Harvard Bioscience (HBIO) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Harvard Bioscience Announces First Quarter 2022 Financial Results
May 4, 2022 7:00 AM EDTÂ Revenue up 7% year-over-year despite volatility in China related to COVID-19 and global supply chain headwinds
HOLLISTON, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the Company) today announced financial results for the first quarter ended March 31, 2022.
Jim Green, Chairman and CEO, said, Our revenue was up 7% on strength from North American sales... More
